^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Excerpt:
Summary of recommendations...Treatment (locoregional and advanced disease)...Second-line ChT for recurrent OS includes ifosfamide or cyclophosphamide, possibly in association with etoposide and/or carboplatin [III, B], and other active drugs including gemcitabine and docetaxel [IV, C], sorafenib [III, B] or regorafenib [II, B].
DOI:
10.1093/annonc/mdy310